Table 10.
Seaweed | Compound Extracted |
Cell Lines/Animals Surveyed |
Route of Administration |
Dosage (μg/mL) | Effect | Reference |
---|---|---|---|---|---|---|
Laminaria cichorioides (Phaeophyceae) |
Sulfated fucan | Human plasma | The lyophilized crude polysaccharide was dissolved in human plasma |
10, 30, 50 | In vitro anticoagulant activity |
[320] |
Fucus evanescens (Phaeophyceae) |
Fucoidans | Human plasma Rat plasma |
Intravenous Injection |
125, 250, 500, 1000 | In vitro and in vivo anticoagulant activity |
[321] |
Gracilaria edulis (Rhodophyceae) |
Phenolic, Flavonoid and Alkaloid compounds |
Bovine serum albumin (protein) |
The extracts were tested on the protein |
20, 40, 60, 80, 100, 120 |
Hypoglycemic activity |
[322] |
Sargassum fulvellum (Phaeophyceae) |
Phlorotannins, grasshopper ketone, fucoidan and polysaccharides |
Mice | Oral administration |
Based on weight of mice |
Antioxidant, anticancer, antiinflammatory, antibacterial, and anticoagulant activities |
[323] |
Griffithsia sp. (Rhodophyceae) |
Griffithsin (protein) | MERS-CoV and SARS-CoV glycoproteins |
The extracts were tested on the proteins |
0.125, 0.25, 0.5, 1, 2 | Antiviral activity against MERS-CoV virus and SARS-CoV glycoprotei |
[324] |
Ulva rigida (Chlorophyceae) |
Ethanolic extract | Twenty-four male Wistar rats |
Oral administration |
500 mL of water with extracts in 2% wt/vol as drinking water for exposed groups per each day (from 3 to 30 days). |
In vivo antihyperglycaemic, antioxidative and genotoxic/ antigenotoxic activities |
[325] |
Saccharina japonica (Phaeophyceae) |
polysaccharides | SARS-CoV-2 S-protein | The extracts were tested on the proteins |
50–500 | In vitro inhibition to SARS-CoV-2 |
[326] |